PPAR-γ agonist rosiglitazone reverses increased cerebral venous hydraulic conductivity during hypertension
- 1 October 2009
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 297 (4) , H1347-H1353
Abstract
Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists have been shown to protect the cerebral vasculature, including the blood-brain barrier. In the present study, we investigated the effect of the PPAR-γ agonist rosiglitazone on changes in venous permeability during chronic hypertension induced by nitric oxide synthase inhibition. Female Sprague-Dawley rats were either treated with NG-nitro-l-arginine methyl ester (l-NAME; 0.5 g/l in drinking water) for 5 wk (HTN; n = 8), l-NAME for 5 wk plus the PPAR-γ agonist rosiglitazone (20 mg/kg in food) for the last 3 wk (HTN + Rosi; n = 5), l-NAME for 5 wk plus the superoxide dismutase mimetic Tempol (1 mmol/l in drinking water) for the last 3 wk (HTN + Tempol; n = 8), or were untreated controls ( n = 9). Fluid filtration ( Jv/ S) and hydraulic conductivity ( Lp) of cerebral veins were compared in vitro between groups after a step increase in pressure from 10 to 25 mmHg to mimic the change in hydrostatic pressure during acute hypertension. Hypertension increased Jv/ S by 2.2-fold and Lp by 3.2-fold. Rosiglitazone treatment after 2 wk of hypertension completely reversed the increased Jv/ S and Lp that occurred during hypertension, whereas Tempol had no effect. These results demonstrate that rosiglitazone was effective at reversing changes in venous permeability that occurred during chronic hypertension, an effect that does not appear to be related to its antioxidant properties. Our findings suggest that PPAR-γ may be a key regulator of blood-brain barrier permeability and a potential therapeutic target during hypertension.Keywords
This publication has 52 references indexed in Scilit:
- VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdownProceedings of the National Academy of Sciences, 2009
- PPARα and PPARγ attenuate HIV‐induced dysrégulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activitiesThe FASEB Journal, 2009
- PPARγ agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanismsBrain Research, 2008
- Interference With PPARγ Signaling Causes Cerebral Vascular Dysfunction, Hypertrophy, and RemodelingHypertension, 2008
- Pioglitazone Exerts Protective Effects Against Stroke in Stroke-Prone Spontaneously Hypertensive Rats, Independently of Blood PressureStroke, 2007
- Pregnancy Prevents Hypertensive Remodeling of Cerebral ArteriesHypertension, 2006
- Renal Effects of Acute Amino Acid Infusion in Hypertension Induced by Chronic Nitric Oxide BlockadeHypertension, 1995
- Evidence that disruption of the blood-brain barrier precedes reduction in cerebral blood flow in hypertensive encephalopathy.Hypertension, 1984
- Effect of chronic hypertension on the blood-brain barrier.Hypertension, 1980
- Cerebral venous pressure during actively induced hypertension and hypercapnia in cats.Stroke, 1980